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Inflammatory breast carcinoma (IBC) is a rare but aggressive tumour associated with poor outcome owing to early metastases.
Increased expression of c-Met protein correlates with reduced survival and high metastatic risk in human cancers including breast
carcinomas and is targetable by specific drugs, that could potentially improve the prognosis. In the present study, we compared c-Met
expression in IBC (n¼41) and non-IBC (n¼480) immunohistochemically (Ventana Benchmark autostainer) in two tissue
microarrays (TMA) along with PI3K and E-cadherin. The results were quantified through an automated image analysis device (SAMBA
Technologies). We observed that (i) c-Met was significantly overexpressed in IBC as compared with non-IBC (Po0.001), (ii) PI3K
was overexpressed (Po0.001) in IBC, suggesting that the overexpressed c-Met is functionally active at least through the PI3K signal
transduction pathway; and (iii) E-cadherin was paradoxically also overexpressed in IBC. We concluded that overexpressed c-Met in
IBC constitutes a potential target for specific therapy for the management of patients with poor-outcome tumours such as IBC.
Automated image analysis of TMA proved to be a valuable tool for high-throughput immunohistochemical quantification of the
expression of intratumorous protein markers.
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Inflammatory breast cancers (IBC) are very aggressive tumours
that most often develop in young women and are associated
with poor 5-year survival ranging from 30 to 50% (Jaiyesimi et al,
1992).
Response to primary chemotherapy including anthracycline-
based neo-adjuvant therapy is a strong but limited indicator of
survival (Buzdar et al, 1995). Clinically, IBC are characterised by
rapid growth, extensive axillary lymph node metastases and
remote metastases at the time of initial diagnosis. Microscopically,
the presence of tumour emboli within dermal lymphatic channels
(associated with skin erythema and/or oedema) constitutes a
major pathologic hallmark of the disease (Tavassoli et al, 2003;
Bertucci et al, 2004; Charafe-Jauffret et al, 2004; Gasparini et al,
2005). In IBC, genes shown as discriminant for aggressiveness are
associated with various cellular functions, in particular cell
motility, angiogenesis and adhesion (Bertucci et al, 2004;
Charafe-Jauffret et al, 2004). The role potential of angiogenesis
on tumour growth and dissemination prompted a search for
therapeutic agents targeting endothelial cells to block angiogenesis
and in vivo tumour growth. Several agents have been assessed in
experimental studies (Pennacchietti et al, 2003; Charafe-Jauffret
et al, 2004), but preliminary results of the clinical studies suggest
that anti-angiogenic therapy through a single agent is not highly
effective in advanced tumours (Pennacchietti et al, 2003; Gasparini
et al, 2005). Recent studies using a combination of antivascular
endothelial growth factor and other therapeutic agents have
renewed interest in this therapeutic strategy (Birchmeier et al,
2003; Pennacchietti et al, 2003; Bertucci et al, 2004; Charafe-
Jauffret et al, 2004; Christensen et al, 2005; Gasparini et al, 2005).
Some of these studies have shown that combination of selective
antiangiogenic and c-Met inhibitors could improve therapeutic
efficiency, resulting in a reduction of both tumour growth and
metastasis. This observation is based on the fact that hypoxia
promotes spread of cancer cells toward a more oxygenated
environment in distant tissues through a transcriptional activation
of c-met proto-oncogene (Pennacchietti et al, 2003; Gasparini et al,
2005).
The c-met proto-oncogene encodes for the high-affinity thyrosin
kinase receptor for hepatocyte growth factor (HGF) or scatter
factor (SF). c-Met and HGF play a major role in cell migration,
morphogenic differentiation, organisation of three-dimensional
tubular structures, cell growth and angiogenesis (Birchmeier et al,
2003; Pennacchietti et al, 2003; Christensen et al, 2005). De-
regulation of c-Met and HGF have been shown to correlate with a
poor outcome in several major human tumours, particularly breast
carcinomas (Beviglia et al, 1997; Ghoussoub et al, 1998; Camp et al,
1999; Nakipoulou et al, 2000; Tolgay Ocal et al, 2003; Christensen
et al, 2005; Lee et al, 2005). In human carcinomas, the receptor
tyrosin kinase c-Met becomes activated through several mechan-
isms, including (i) overexpression and constitutive kinase
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paracrine and autocrine activation, (iii) upregulation by mutation
or epigenetic mechanisms such as secreted growth factors, tumour
hypoxia and activation of other oncogenes (Birchmeier et al, 2003;
Pennacchietti et al, 2003; Christensen et al, 2005). Various c-Met
inhibitors have recently been developed and experimentally
evaluated as potential drugs for treatment of human cancers
(Maulik et al, 2002; Trusolino and Comoglio, 2002; Ma et al, 2003;
Christensen et al, 2005). Thus, overexpression of c-Met can be
targeted by specific inhibitors (Maulik et al, 2002; Trusolino and
Comoglio, 2002; Ma et al, 2003; Christensen et al, 2005), and
immunohistochemically detected overexpression within tumour
biopsies at the time of diagnosis may be relevant for patient
management. c-Met expression has never been specifically
evaluated in IBC. As tumour cell dissemination to distant sites
and metastases are responsible for early patient death, we
hypothesised that c-Met could be overexpressed and significantly
involved in the process of IBC metastasis and that specific therapy
could improve the prognosis for these patients.
In this study, our goal was to evaluate c-Met expression in IBC,
parallel with phosphatidylinositol-3-kinase PI3K transductal signal
expression. E-cadherin expression was also evaluated, in view of
previous results unexpectedly showing overexpression in IBC and
subsequent paradoxically increased cell–cell adhesion in highly
metastatic tumours (Charafe-Jauffret et al, 2004). We investigated
c-Met immunocytochemical expression in 41 IBC and compared it
with that in a control of 480 not otherwise specified ductal breast
carcinomas. For this purpose, we constructed tissue microarrays
(TMA) (Kallioniemi et al, 2001) specifically dedicated to IBC and
480 non-IBC of various grades, sizes and nodal status, and
quantified c-Met immunoprecipitates within the tumour TMA
using specific software recently developed for image analysis
(SAMBA 2050).
MATERIALS AND METHODS
Breast tumour samples and patient characteristics
Inflammatory breast carcinoma samples were obtained from 41
patients who had undergone initial surgery in the Ho ˆpital de la
Conception (PB). Tissue fragments were processed in the
Pathology Department, Ho ˆpital Nord (SG, CC, LA, SCM). Tumours
were selected according to the pTNM classification as pT4d with
superficial dermal lymphatic invasion within a skin biopsy
sampled at the time of initial diagnosis assessed on surgical
tumour biopsy. All tumours selected as IBC were axillary node-
positive, oestrogen- and progesterone-receptor-negative, as eval-
uated by immunohistochemistry (with positivity cut-off value of
1%), P53-positive and HER-2-positive FISH amplification/Ventana
Benchmark X6) grade 3 ductal carcinomas with inflammatory
stroma and prominent vascular invasion. The IBC were compared
with 480 non-IBC ductal breast carcinomas selected from our
archival tumour paraffin blocks. Tumour size varied from 7 to
65mm (m¼23mm, s.d.78). All tumours were ductal carcinomas
not otherwise specified; other subtypes, particularly lobular and
medullary carcinomas present in our files, were excluded because
of their specific reactivity with regard to E-cadherin. Ductal
carcinomas were grade 1 (103 out of 480), grade 2 (270 out of 480)
and grade 3 (107 out of 480), and 312 of the patients were node-
negative. All tumour biopsies used for TMA construction were
fixed in buffered formalin, paraffin-embedded and stored at
controlled temperature (18–221C).
Tissue microarrays construction
Tissue microarrays were prepared as previously described
(Ginestier et al, 2002; Charpin et al, 2004). Briefly, for each
tumour, two representative tumour areas were delineated by
circling within tissue sections (SG, CC, JD, SCM) appropriate areas
with a permanent black pen on H&E-stained paraffin sections, to
guide the technicians’ punches of cores within the primary paraffin
block. Cores were sampled using the ALPHELYS Arraying Device
(ALPHELYS, 78370 Plaisir, France). Core cylinders of 0.6mm
diameter, punched from the donor block, were then deposited in
the recipient paraffin block. Tissue microarray sections (4mm
thick) were cut 24h before immunohistochemical processing.
Immunohistochemical automated procedure
The IHC procedure was performed with a Ventana Benchmark
autostainer using the procedure previously reported (Charpin
et al, 2004; Dale `s et al, 2004, 2005) and specific antibodies: mouse
monoclonal anti-c-Met (clone 8F11, diluted 1:20) was obtained
from Novocastra (TEBU, France); polyclonal rabbit anti-PI3K p110
a (diluted 1:10) from Cell Signaling (Ozyme, France); monoclonal
mouse anti E-cadherin (clone 4A 2C7, diluted 1:100) from
Clinisciences (France).
Slides were incubated for 32min at 371C with specific primary
antibodies.
Diaminobenzidine or 3-amino-9-ethylcarbazole were used as
chromogens and slides were counterstained with haematoxylin
before mounting. Both chromogens used on regular full sections
before TMA testing gave concordant results in terms of both
surfaces and intensities of immunostaining. Negative controls were
obtained by omitting the specific primary antibodies.
Preliminary validation of immunodetection and TMA
Comparison of c-Met immunoexpression in paraffin and frozen
sections c-Met immunoexpression in 120 paraffin sections was
compared with that in 120 frozen sections from tissue blocks
sampled in the same tumours. In a preliminary study, we observed
that c-Met expression in frozen samples of breast carcinoma
correlated with poor survival (unpublished data). Comparison of
c-Met immunostaining by semiquantitative evaluation and in
paraffin sections by Ventana Benchmark device antigen retrieval
gave similar results and immunostaining patterns were signifi-
cantly correlated in both substrates (Spearman’s correlation
coefficient r¼0.694, Po0.01).
Comparison of c-Met expression in different cores punched from the
same tumour Evaluation of c-Met immunoexpression in 50 cases
of breast carcinoma selected for TMA showed similar immuno-
staining in multiple core samples from different areas (but of
similar cellularity) of the donor blocks (Spearman’s correlation
coefficient r¼0.784, Po0.01). This indicates that a limited
number (two in the present study) of cores was sufficient when
areas in the donor blocks were appropriately delineated and
representative of tumours.
Comparison of semiquantitative analysis and quantitative image
analysis A semiquantitative approach was used to classify
immunoexpression as negative or positive. The latter were further
subclassified into weak (1þ), intermediate (2þ) or intense (3þ)
staining, based on the intensity of immunoreaction. This approach
gave results that were significantly correlated (Spearman’s
correlation coefficient r¼0.698, Po0.01) with the densitometric
quantification of immunoreactivity assessed by SAMBA image
analysis.
Image analysis
Tissue microarray analysis using the SAMBA 2050 automated
device (SAMBA Technologies, Meylan, Grenoble, France) was
performed according to the following protocol.
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magnification ( 2, pixel dimension 3.7mm). This image was made
of a mosaic of images acquired along a rectangular grid with
contiguous fields. Second, the area of the slide containing the
TMA cores was automatically delineated and scanned at higher
magnification ( 10, pixel dimension 7.4mm). Third, after
autofocus, the images were acquired with an overlap greater than
the largest mechanical positioning error. Using the image contents,
a matching algorithm precisely determined the relative position of
each image with respect to its neighbours. Calculated overlap was
removed from images to produce a new set of higher magnification
( 10) images, thus covering precisely the cores of interest. A
specifically developed tool referred to as TMA crop then allowed
superimposition of the TMA grid onto the reduced image and
precise alignment of each node of the grid with the core location
within the image (Figure 1). The final step was performed
automatically using the core image contents to ensure pixel
precision of the match. From the images acquired with  20
magnification, a new set of images was next computed, one for
each core. After colour analysis of the core images, SAMBA
‘immuno’ software was applied as previously reported (Charpin
et al, 1994, 1997a,b, 1998a,b,c, 2004; Dale `s et al, 2004, 2005) in
regular full tissue sections. Several parameters per core were
computed: the area of counterstaining, the ratio (as percentage) of
the positive area vs counterstained areas and a quick score
(percentage of positive area mean optical density). Optical
density (OD) was evaluated on a scale of grey levels (arbitrary
units) ranging from 0 (100% transmission, OD¼0) to 255 (1%
transmission OD¼2). The computation of each parameter
obtained provided numerical values consisting of continuous
variables for statistical tests.
Statistical analysis
Statistical analyses were performed using NCSS 2005 and Statistica
Statistical softwares.
The concordance between the immunoexpression data
(i) in frozen and fixed tissues, (ii) in full section and TMA
sections and (iii) by semiquantitative and automated analysis were
examined using Spearman rank correlation. Comparisons of mean
parameter values for c-Met, PI3K and E-cadherin were assessed
through non-parametric tests. Mean values were computed from
measurements in the two cores from each tumour, before
correlation between IBC and non-IBC. Contingency table analysis
was used to analyse the relationship between protein expression in
TMA of the IBC and non-IBC groups (Mann–Whitney, Kolgo-
morov and w
2 tests). All P-values were two-sided. In the study,
mean immunostained surfaces and quick scores were  10,
because absolute values of measurements corresponded to very
small numbers.
RESULTS
c-Met expression in TMA
c-Met immunostaining appeared on the tissue sections as dense
cytoplasmic staining, irregularly distributed within carcinomatous
cells (Figure 2), with focal strong enhancement beneath the plasma
membrane.
The c-Met expression was significantly greater in IBC
for each parameter assessed by software (Table 1), as shown
in particular by a higher mean percentage of immunostained
surface (21.3 vs 2.7%) (Po0.001, Mann–Whitney and Kolgomorov
tests) and lower SAMBA quick scores (0.48 vs 5.5)
Po0.001, Mann–Whitney and Kolgomorov tests). The much
stronger intensity of staining explained the lower quick
scores (arbitrary scale of grey levels: 0 for black to 255 for
white).
None of the IBC was c-Met-negative (n¼0 out of 41), whereas
about one-third of the control group was negative (n¼174 out of
480, Po0.001, w
2).
Figure 1 Steps of SAMBA software processing before densitometry on TMA. (A) Reference grid, (B, C) precrop of digitised TMA and surimposed grid
(D) cropped final image before image analysis (densitometry).
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Phosphatidylinositol-3-kinase immunostaining appeared irregu-
larly distributed in the cytoplasm of carcinomatous cells (Figure 3).
The PI3K staining was significantly greater in IBC than in the
control group: immunostained surfaces 19.6 and 4.4%, Po0.001
and mean quick scores 0.13 vs 5.7, P¼0.0019 (Mann–Whitney).
Most IBC were PI3K-positive (n¼35 out of 41), whereas the
positive/negative ratio was lower in the control group (n¼287 out
of 480, Po0.01, w
2).
E-cadherin expression in TMA
E-cadherin was observed along the cytoplasmic membrane
(Figure 4).
Figure 2 Variation of c-Met cytoplasmic immunostaining stronger in IBC TMA (A, B) with some focal enhancement beneath the plasma membrane (C),
than in ductal non-IBC TMA (D).
Table 1 Immunohistochemical expression of c-Met, PI3K, E-cadherin in IBC (inflammatory breast carcinomas) and in noninflammatory control ductal
breast carcinoma series, measured by automated densitometry through image analysis, SAMBA 2050 (mean values 10/*Mann–Whitney test; **w
2 tests).
Immunostained surface (%) SAMBA quick score Pos/neg cases
Mean Mean Positive Negative
c-Met
Inflammatory breast cancers (n¼41) 21.3% (s.d.¼2.6) 0.48 (s.d.¼0.18) 41/41 0/41
*Po0.001 *Po0.001 P**o0.001
Control series of non-inflammatory breast carcinomas (n¼480) 2.7% (s.d.¼0.81) 5.5 (s.d.¼0.53) 306/480 174/480
PI3K
Inflammatory breast cancers (n¼41) 19.6% (s.d.¼2.4) 0.13 (s.d.¼0.002) 35/41 06/41
*P¼0.0019 *Po0.001 P**o0.01
Control series of non-inflammatory breast carcinomas (n¼480) 4.4% (s.d.¼38) 5.7 (s.d.¼0.002) 287/480 193/480
E-cadherin
Inflammatory breast cancers (n¼41) 35.4% (s.d.¼5.2) 5.2 (s.d.¼2.1) 41/4 0/41
*Po0.001 *P¼NS
Control series of non-inflammatory breast carcinomas (n¼480) 10.3% (s.d.¼1.04) 6.7 (s.d.¼2.09) 480/480 0/480
Abbreviations: PI3K¼phosphatidylinositol-3-kinase; s.d.¼standard deviation.
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(mean optical density), were significantly different between IBC
and non-IBC (35.4 and 10.3%, respectively; Po0.001, Mann–
Whitney) (Table 1). All tumours (ductal carcinomas) were E-
cadherin-positive at least focally in both IBC and non-IBC groups
(w
2 test not performed).
DISCUSSION
Tissue microarrays have been developed to provide cost-effective
substrates for high-throughput molecular profiling of tumours and
are particularly useful in breast cancer analysis, as shown in
several previous reports (Kallioniemi et al, 2001; Ginestier et al,
2002; Bertucci et al, 2004; Charpin et al, 2004). However, only one
study has recently documented c-Met immunoexpression in TMA
from 324 breast carcinomas (Tolgay Ocal et al, 2003), showing a
worse outcome of node-negative breast carcinomas that over-
expressed c-Met.
In the present study using TMA, we confirmed the increased c-
Met expression in IBC previously documented by others in non-
TMA substrates of aggressive phenotypes of breast cancer (Beviglia
et al, 1997; Ghoussoub et al, 1998). Recent experimental results
have shown that the c-Met receptor and c-Met-dependent
signalling can be specifically inhibited (Christensen et al, 2005),
similar to therapies targeting other molecules with, for example,
mutant c-Kit in gastrointestinal stromal tumours, trastuzumab in
breast cancers overexpressing HER-2, bevacizumab in colorectal
carcinoma and genitinib in non-small-cell lung cancer (Birchmeier
et al, 2003; Christensen et al, 2005). However, initial attempts using
in vivo models of small-molecule therapy, based on inhibition of
RTKs by Glivec, Iressa and Tarceva that are used for treatment of
multiple human cancers, have revealed a lack of selectivity towards
c-Met inhibition (Maulik et al, 2002; Ma et al, 2003; Pennacchietti
et al, 2003; Christensen et al, 2005; Gasparini et al, 2005).
Some approaches specifically to inhibit HGF or c-Met-depen-
dent signalling have been explored (Christensen et al, 2003; Laird
et al, 2003; Matsumoto and Nakamura, 2003; Morton et al, 2003;
Wang et al, 2003; Zheng et al, 2003; Schwall et al, 2004). Recently,
various studies have reported very efficient and selective small
molecule inhibitors of c-Met, characterised by the indolin-2-one
core structure, such as PH A665752 and Kirin (Christensen et al,
2003). Functional assays have indicated that these small molecules
inhibit c-Met functions that are dependent on the kinase activity
of the receptor, and act upon differential regulation of signalling
through inhibition of PI3K or FAK and c-SRC pathways
(Christensen et al, 2003, 2005; Wang et al, 2003). The fact that
we found PI3K to be concomitantly overexpressed with c-Met
supports the hypothesis that c-Met activation in IBC induces
downstream signalling through the PI3K pathway. Collectively, all
these data support the notion that c-Met is a potential therapeutic
target for either small molecules or biological inhibitors of
Figure 3 Phosphatidylinositol-3-kinase cytoplasmic immunostaining in (A) IBC TMA in (B) non-inflammatory ductal carcinoma.
Figure 4 Linear E-cadherin distribution along tumour cell membranes in IBC TMA (A, B).
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tumour cells that would be of value in the management of patients
with IBC.
Loss of epithelial cell adhesion molecules of carcinomatous cells
is also partly responsible for tumour spreading. E-cadherin is a
transmembrane protein that mediates cell–cell adhesion in
epithelial tissues. It connects epithelial cells through its association
with catenins, which anchors E-cadherin to cells in the cytoske-
leton, and thus aids in maintaining cell–cell adhesion (Birchmeier
et al, 2003; Christensen et al, 2005; Gasparini et al, 2005).
Hepatocyte growth factor/scatter factor stimulation reduces b-
catenin binding to the intracellular portion of E-cadherin, resulting
in loss of cell–cell adhesion (Birchmeier et al, 2003; Christensen
et al, 2005; Gasparini et al, 2005). Increased HGF/c-Met stimula-
tion may therefore play a role in altering cell adhesion in human
cancers overexpressing c-Met. In breast carcinomas, mutation of
the gene encoding E-cadherin is responsible for low expression of
the protein in tumours associated with a poor outcome and
frequent remote metastases Charpin et al. (1998c). Lobular
carcinomas are now well recognised as tumours having a mutation
of the gene encoding E-cadherin, a lack of E-cadherin immuno-
histochemical expression, and a particular phenotype and micro-
scopic pattern with a typical permeation throughout the breast
tissue by isolated cells and small nests of tumour cells. In contrast,
IBC have surprisingly been reported to overexpress E-cadherin see
review in (Charafe-Jauffret et al, 2004). Similarly, in our study, IBC
exhibited significantly increased E-cadherin expression. Overall,
these data suggest that in IBC, overexpression of c-Met may act
upon cell adhesion and spreading in spite of preserved or even
overexpressed E-cadherin. The overexpressed E-cadherin is either
inefficient or more likely retains strong homotypic tumour cell–
tumour cell adhesion capacity, producing compact spheroids,
while tumour cell–endothelial cell aversion develops, favouring
dissemination of tumour emboli. This aversion has been reported
to result from non-functional cytoplasmic glycosylates (MUC1)
with subsequent lack of tumour-cell binding to E-selectin at the
endothelial surface (Bertucci et al, 2004; Charafe-Jauffret et al,
2004).
Developments in research and routine practice in pathology
have followed progress in molecular biology, permitting the
development of TMA for validation of immunocytochemical
assays in a large number of tumours (Kallioniemi et al, 2001;
Ginestier et al, 2002). Nevertheless, construction of TMA requires
(a) some technical experience to evaluate available tumour
markers for widespread use, (b) the availability of large tumour
libraries to allow documentation of marker expression in tissues
and (c) the ability of pathologists to select archival tissues and to
collect patient follow-up data. Although semiquantitative evalua-
tion of TMA is very difficult and time-consuming for pathologists
and may be a source of non-reproducible interpretation using
arbitrary methods for scoring of immunostaining and lack of
quality control, limited data are available in the literature
concerning the automated quantification of immunoprecipitates
on TMA (Camp et al, 2002; Pages et al, 2006). However,
appropriate software dedicated to immunocytochemical tissue
labelling, along with the latest image analysis devices, can
considerably facilitate the rapid, high-throughput measurement
of immunostaining in hundreds of immunostained cores within
TMA tissue sections, with completely automated digitisation of
microscopic slides (up to 50 slides per batch) in only a few hours.
Such combinations of hardware and software allow quantified
assessment of immunoprecipitates, providing continuous
values for the usual parameters of measurement suitable for
statistical computation, and are also particularly helpful for
distinguishing minor differences in staining surfaces and inten-
sities that are nearly impossible to detect by a pathologist on
microscopic examination (Charpin et al, 1994, 1997a,b, 1998a,b,c,
2004).
On the basis of our experience with image analysis, we have
developed TMA suitable for automated quantitative analysis and
applied dedicated software to densitometry in TMA in order to
compare expression of c-Met and downstream transduction signals
like PI3K immunohistochemically in IBC and non-IBC. Our results
confirm that c-Met and PI3K are significantly overexpressed in
IBC, suggesting that in this particular clinical setting, c-Met
expression and downstream signal transducers may be regarded as
potential targets for specific therapies. Also, overexpression of
c-Met as well as E-cadherin appears to belong to the proteomic
signature of IBC.
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